

Chapter 83

REFERENCES

1. Baldini M, Costea N, Dameshek W. The viability of stored human platelets. *Blood*. 1960;16:1669-1692.
2. Rapaport SI, Ames SB, Mikkelsen S. The levels of antihemophilic globulin and proaccelerin in fresh and bank blood. *Am J Clin Pathol*. 1959;31:297-304.
3. Valeri CR, Pivacek LE, Ouellet R, Gray A. A comparison of methods of determining the 100 percent survival of preserved red cells. *Transfusion*. 1984;24:105-108.
4. Beutler E, Wood L. The in vivo regeneration of red cell 2,3 diphosphoglyceric acid (DPG) after transfusion of stored blood. *J Lab Clin Med*. 1969;74:300-304.
5. Blajchman MA. Allogeneic blood transfusions, immunomodulation, and postoperative bacterial infection: do we have the answers yet? *Transfusion*. 1997;37:121-125.
6. Menitove JE, McElligott MC, Aster RH. Febrile transfusion reaction: what blood component should be given next? *Vox Sang*. 1982;42:318-321.
7. Tejada F, Bias WB, Santos GW, Zieve PD. Immunologic response of patients with acute leukemia to platelet transfusions. *Blood*. 1973;42:405-412.
8. American Association of Blood Banks. *Standards for Blood Banks and Transfusion Services*. 24th ed. Washington, DC: AABB; 2006.
9. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. *N Engl J Med*. 1997;337:1861-1869.
10. Yap PL, Pryde EA, McClelland DB. IgA content of frozen-thawed-washed red blood cells and blood products measured by radioimmunoassay. *Transfusion*. 1982;22:36-38.
11. Valeri CR. Factors influencing the 24-hour posttransfusion survival and the oxygen transport function of previously frozen red cells preserved with 40 per cent W-V glycerol and frozen at -80°C . *Transfusion*. 1974;14:1-15.
12. Valeri CR, Zaroulis CG. Rejuvenation and freezing of outdated stored human red cells. *N Engl J Med*. 1972;287:1307-1313.
13. Consensus conference. Prevention and treatment of kidney stones. *JAMA*. 1988;260:977-981.
14. Wilkerson DK, Rosen AL, Sehgal LR, Gould SA, Sehgal HL, Moss GS. Limits of cardiac compensation in anemic baboons. *Surgery*. 1988;103:665-670.
15. Levy PS, Kim SJ, Eckel PK, et al. Limit to cardiac compensation during acute isovolemic hemodilution: influence of coronary stenosis. *Am J Physiol*. 1993;265:H340-H349.
16. Levy PS, Chavez RP, Crystal GJ, et al. Oxygen extraction ratio: a valid indicator of transfusion need in limited coronary vascular reserve? *J Trauma*. 1992;32:769-773; discussion 773-764.
17. Sanders MR, Graeber JE. Posttransfusion graft-versus-host disease in infancy. *J Pediatr*. 1990;117:159-163.
18. Hillyer CD, Emmens RK, Zago-Novaretti M, Berkman EM. Methods for the reduction of transfusion-transmitted cytomegalovirus infection: filtration versus the use of seronegative donor units. *Transfusion*. 1994;34:929-934.
19. Goldman M, Delage G. The role of leukodepletion in the control of transfusion-transmitted disease. *Transfus Med Rev*. 1995;9:9-19.
20. Murphy WG, McClelland DB. Deceptively low morbidity from failure to practice safe blood transfusion: an analysis of serious blood transfusion errors. *Vox Sang*. 1989;57:59-62.
21. Pineda AA, Taswell HF, Brzica SM Jr. Transfusion reaction. An immunologic hazard of blood transfusion. *Transfusion*. 1978;18:1-7.
22. Silberstein L, Spitalnik Q. *Blood Group Antigens and Antibodies*. Baltimore: Williams & Wilkins; 1996.
23. Hoeltge GA, Domen RE, Rybicki LA, Schaffer PA. Multiple red cell transfusions and alloimmunization. Experience with 6996 antibodies detected in a total of 159,262 patients from 1985 to 1993. *Arch Pathol Lab Med*. 1995;119:42-45.
24. Schulman I. Controversies in red cell compatibility testing. In: Nance S, ed. *Immune Destruction of Red Blood Cells*. Washington, DC: American Association of Blood Banks; 1989:171-199.
25. Garratty G. Factors affecting the pathogenicity of red cell auto- and alloantibodies. In: Nance S, ed. *Immune Destruction of Red Blood Cells*. Washington, DC: American Association of Blood Banks; 1987:109-157.
26. Ramsey G, Cornell FW, Hahn LF, Larson P, Issitt LB, Starzl TE. Red cell antibody problems in 1000 liver transplants. *Transfusion*. 1989;29:396-400.
27. Lane TA, Anderson KC, Goodnough LT, et al. Leukocyte reduction in blood component therapy. *Ann Intern Med*. 1992;117:151-162.
28. Walker RH. Special report: transfusion risks. *Am J Clin Pathol*. 1987;88:374-378.
29. Linden JV, Paul B, Dressler KP. A report of 104 transfusion errors in New York State. *Transfusion*. 1992;32:601-606.
30. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. *Transfusion*. 1990;30:583-590.

31. Davenport RD, Kunkel SL. Cytokine roles in hemolytic and nonhemolytic transfusion reactions. *Transfus Med Rev.* 1994;8:157-168.
32. Beauregard P, Blajchman MA. Hemolytic and pseudo-hemolytic transfusion reactions: an overview of the hemolytic transfusion reactions and the clinical conditions that mimic them. *Transfus Med Rev.* 1994;8:184-199.
33. Jenner P, Holland P. Diagnosis and management of transfusion reactions. In: Petz L, Swisher S, Kleinman S, eds. *Clinical Practice of Transfusion Medicine.* New York: Churchill Livingstone; 1996:905-927.
34. Goldfinger D. Acute hemolytic transfusion reactions—a fresh look at pathogenesis and considerations regarding therapy. *Transfusion.* 1977;17:85-98.
35. Fudenberg H, Allen FH Jr. Transfusion reactions in the absence of demonstrable incompatibility. *N Engl J Med.* 1957;256:1180-1184.
36. Consensus conference. Fresh-frozen plasma. Indications and risks. *JAMA.* 1985;253:551-553.
37. McVay PA, Toy PT. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. *Transfusion.* 1991;31:164-171.
38. Nusbacher J. Blood transfusion support in liver transplantation. *Transfus Med Rev.* 1991;5:207-213.
39. Mannucci PM, Federici AB, Sirchia G. Hemostasis testing during massive blood replacement. A study of 172 cases. *Vox Sang.* 1982;42:113-123.
40. Harke H, Rahman S. Haemostatic disorders in massive transfusion. *Bibl Haematol.* 1980:179-188.
41. Duchesne JC, Hunt JP, Wahl G, et al. Review of current blood transfusions strategies in a mature level I trauma center: were we wrong for the last 60 years? *J Trauma.* 2008;65:272-276; discussion 276-278.
42. Sihler KC, Napolitano LM. Massive transfusion: new insights. *Chest.* 2009;136:1654-1667.
43. Colman RW, Robboy SJ, Minna JD. Disseminated intravascular coagulation: a reappraisal. *Annu Rev Med.* 1979;30:359-374.
44. Welsby IJ, Monroe DM, Lawson JH, Hoffmann M. Recombinant activated factor VII and the anaesthetist. *Anaesthesia.* 2005;60:1203-1212.
45. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists. *JAMA.* 1994;271:777-781.
46. Martin JN Jr, Files JC, Blake PG, Perry KG Jr, Morrison JC, Norman PH. Postpartum plasma exchange for atypical preeclampsia-eclampsia as HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. *Am J Obstet Gynecol.* 1995;172:1107-1125; discussion 1125-1107.
47. Novitzky N, Jacobs P, Rosenstrauch W. The treatment of thrombotic thrombocytopenic purpura: plasma infusion or exchange? *Br J Haematol.* 1994;87:317-320.
48. Cowan PJ, Aminian A, Barlow H, et al. Protective effects of recombinant human antithrombin III in pig-to-primate renal xenotransplantation. *Am J Transplant.* 2002;2:520-525.
49. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. *N Engl J Med.* 1998;339:1585-1594.
50. Rock G, Shumak KH, Sutton DM, Buskard NA, Nair RC. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. *Br J Haematol.* 1996;94:383-386.
51. Ching EP, Poon MC, Neurath D, Ruether BA. Red blood cell alloimmunization complicating plasma transfusion. *Am J Clin Pathol.* 1991;96:201-202.
52. Pineda AA, Taswell HF. Transfusion reactions associated with anti-IgA antibodies: report of four cases and review of the literature. *Transfusion.* 1975;15:10-15.
53. Bowden R, Sayers M. The risk of transmitting cytomegalovirus infection by fresh frozen plasma. *Transfusion.* 1990;30:762-763.
54. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. *N Engl J Med.* 1991;325:73-80.
55. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. *Ann Intern Med.* 1988;109:783-788.
56. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA. Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. *JAMA.* 1995;273:1865-1870.
57. Keith L, Bozorgi N. Small dose anti-Rh therapy after first trimester abortion. *Int J Gynaecol Obstet.* 1977;15:235-237.
58. Bowman JM, Chown B, Lewis M, Pollock JM. Rh isoimmunization during pregnancy: antenatal prophylaxis. *Can Med Assoc J.* 1978;118:623-627.
59. Rodeghiero F, Castaman G, Meyer D, Mannucci PM. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. *Vox Sang.* 1992;62:193-199.
60. Martinowitz U, Schulman S, Horoszowski H, Heim M. Role of fibrin sealants in surgical procedures on patients with hemostatic disorders. *Clin Orthop Relat Res.* 1996:65-75.
61. McCarthy PM. Fibrin glue in cardiothoracic surgery. *Transfus Med Rev.* 1993;7:173-179.
62. Spotnitz WD, Dalton MS, Baker JW, Nolan SP. Successful use of fibrin glue during 2 years of surgery at a university medical center. *Am Surg.* 1989;55:166-168.
63. Berguer R, Staerkel RL, Moore EE, Moore FA, Galloway WB, Mockus MB. Warning: fatal reaction to the use of fibrin glue in deep hepatic wounds. Case reports. *J Trauma.* 1991;31:408-411.
64. Janson PA, Jubelirer SJ, Weinstein MJ, Deykin D. Treatment of the bleeding tendency in uremia with cryoprecipitate. *N Engl J Med.* 1980;303:1318-1322.
65. Triulzi DJ, Blumberg N. Variability in response to cryoprecipitate treatment for hemostatic defects in uremia. *Yale J Biol Med.* 1990;63:1-7.
66. Hoffmann R, Benz E, Shattil S, eds. *Hematology: Basic Principles and Practice.* Philadelphia: Elsevier; 2005.
67. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. *Nature.* 1984;312:326-330.
68. Teitel JM. Safety of coagulation factor concentrates. *Haemophilia.* 1998;4:393-401.
69. Mannucci PM, Carlsson S, Harris AS. Desmopressin, surgery and thrombosis. *Thromb Haemost.* 1994;71:154-155.

70. Lusher JM. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors—benefits and limitations. *Semin Hematol.* 1994;31:49-52.
71. Roberts HR. Clinical experience with activated factor VII: focus on safety aspects. *Blood Coagul Fibrinolysis.* 1998;9 (1 Suppl):S115-S118.
72. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. *Lancet.* 1992;339:594-598.
73. Lusher JM. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors—benefits and limitations. *Semin Hematol.* 1994;31:49-52.
74. American Society of Anesthesiologists Practice Guidelines for Perioperative Blood Transfusion and Adjuvant Therapies. <http://www.asahq.org/publicationsAndServices/practiceparam.htm#blood>.
75. Dickneite G, Dorr B, Kaspereit F, Tanaka KA. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model. *J Trauma.* 68:1151-1157.
76. Karlsson M, Ternstrom L, Hyllner M, et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. *Thromb Haemost.* 2009;102:137-144.
77. Gill R, Herbertson M, Vuylsteke A, et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. *Circulation.* 2009;120:21-27.
78. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med.* 2001;344:699-709.
79. Murphy S. Platelet function, kinetics, and metabolism: impact on quality assessment, storage, and clinical use. In: McLeod B, Price T, Drew M, eds. *Apheresis: Principles and Practice.* Bethesda, MD: AABB Press; 1997:123.
80. Read MS, Reddick RL, Bode AP, et al. Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: potential for long-term storage of dried platelets for transfusion. *Proc Natl Acad Sci U S A.* 1995;92:397-401.
81. McCullough J, Steeper TA, Connelly DP, Jackson B, Huntington S, Scott EP. Platelet utilization in a university hospital. *JAMA.* 1988;259:2414-2418.
82. Rebullà P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. *N Engl J Med.* 1997;337:1870-1875.
83. Platelet transfusion therapy. National Institutes of Health Consensus Conference. *Transfus Med Rev.* 1987;1:195-200.
84. Poon MC, d'Oiron R. Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. *Blood Coagul Fibrinolysis.* 2000;11(1 Suppl):S55-S68.
85. Poon MC, D'Oiron R, Von Depka M, et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. *J Thromb Haemost.* 2004;2:1096-1103.
86. Heyman M, Schiffer C. Platelet transfusion to patients receiving chemotherapy. In: Rossi E, Simon T, Moss G, eds. *Principles of Transfusion Medicine.* Baltimore: Williams & Wilkins; 1996:263.
87. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. *Transfusion.* 2009;49(2 Suppl):1S-29S.
88. Hillyer CD, Josephson CD, Blajchman MA, Vostal JG, Epstein JS, Goodman JL. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. *Hematology Am Soc Hematol Educ Program.* 2003:575-589.
89. Brecher ME, Hay SN. Bacterial contamination of blood components. *Clin Microbiol Rev.* 2005;18:195-204.
90. Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. *Transfus Med Rev.* 2003;17:120-162.
91. Blajchman MA, Goldman M. Bacterial contamination of platelet concentrates: incidence, significance, and prevention. *Semin Hematol.* 2001;38:20-26.
92. Dumont LJ, Kleinman S, Murphy JR, et al. Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results. *Transfusion.* 2009;50:598-599.
93. Kleinman S, Dumont LJ, Tomasulo P, et al. The impact of discontinuation of 7-day storage of apheresis platelets (PASSPORT) on recipient safety: an illustration of the need for proper risk assessments. *Transfusion.* 2009;49:903-912.
94. Brecher ME, Holland PV, Pineda AA, Tegtmeyer GE, Yomtovian R. Growth of bacteria in inoculated platelets: implications for bacteria detection and the extension of platelet storage. *Transfusion.* 2000;40:1308-1312.
95. Zou S, Notari EPT, Stramer SL, Wahab F, Musavi F, Dodd RY. Patterns of age- and sex-specific prevalence of major blood-borne infections in United States blood donors, 1995 to 2002: American Red Cross blood donor study. *Transfusion.* 2004;44:1640-1647.
96. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. *N Engl J Med.* 2004;351:760-768.
97. Koenigbauer UF, Eastlund T, Day JW. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. *Transfusion.* 2000;40:1203-1206.
98. Hollinger FB, Kleinman S. Transfusion transmission of West Nile virus: a merging of historical and contemporary perspectives. *Transfusion.* 2003;43:992-997.
99. Macedo de Oliveira A, Beecham BD, Montgomery SP, et al. West Nile virus blood transfusion-related infection despite nucleic acid testing. *Transfusion.* 2004;44:1695-1699.
100. Allain JP, Bianco C, Blajchman MA, et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. *Transfus Med Rev.* 2005;19:110-126.
101. de Rie MA, van der Plas-van Dalen CM, Engelfriet CP, von dem Borne AE. The serology of febrile transfusion reactions. *Vox Sang.* 1985;49:126-134.
102. Stack G, Snyder EL. Cytokine generation in stored platelet concentrates. *Transfusion.* 1994;34:20-25.
103. Stack G, Baril L, Napychank P, Snyder EL. Cytokine generation in stored, white cell-reduced, and bacterially contaminated units of red cells. *Transfusion.* 1995;35:199-203.
104. Heddle NM, Klama L, Singer J, et al. The role of the plasma from platelet concentrates in transfusion reactions. *N Engl J Med.* 1994;331:625-628.
105. Mangano MM, Chambers LA, Kruskall MS. Limited efficacy of leukopoor platelets for prevention of febrile transfusion reactions. *Am J Clin Pathol.* 1991;95:733-738.

106. Snyder EL, Mechanic S, Baril L, Davenport R. Removal of soluble biologic response modifiers (complement and chemokines) by a bedside white cell-reduction filter. *Transfusion*. 1996;36:707-713.
107. Meryman HT, Hornblower M. The preparation of red cells depleted of leukocytes. Review and evaluation. *Transfusion*. 1986;26:101-106.
108. Shiba M, Tadokoro K, Sawanobori M, Nakajima K, Suzuki K, Juji T. Activation of the contact system by filtration of platelet concentrates with a negatively charged white cell-removal filter and measurement of venous blood bradykinin level in patients who received filtered platelets. *Transfusion*. 1997;37:457-462.
109. Snyder EL, Bookbinder M. Role of microaggregate blood filtration in clinical medicine. *Transfusion*. 1983;23:460-470.
110. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA. Proceedings of a consensus conference: towards an understanding of TRALI. *Transfus Med Rev*. 2005;19:2-31.
111. Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. *Crit Care Med*. 2005;33:721-726.
112. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am J Respir Crit Care Med*. 1994;149:818-824.
113. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. *Transfusion*. 1985;25:573-577.
114. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. *Transfusion*. 2004;44:1774-1789.
115. Silliman CC, McLaughlin NJ. Transfusion-related acute lung injury. *Blood Rev*. 2006;20:139-159.
116. Eder AF, Herron R, Strupp A, et al. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. *Transfusion*. 2007;47:599-607.
117. Kopko PM, Popovsky MA, MacKenzie MR, Paglieroni TG, Muto KN, Holland PV. HLA class II antibodies in transfusion-related acute lung injury. *Transfusion*. 2001;41:1244-1248.
118. Popovsky MA, Chaplin HC Jr, Moore SB. Transfusion-related acute lung injury: a neglected, serious complication of hemotherapy. *Transfusion*. 1992;32:589-592.
119. Triulzi DJ. Transfusion-related acute lung injury: current concepts for the clinician. *Anesth Analg*. 2009;108:770-776.
120. Chapman CE, Stainsby D, Jones H, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. *Transfusion*. 2009;49:440-452.
121. Eder AF, Herron RM Jr, Strupp A, et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). *Transfusion*. 2010;50:1732-1742.
122. Middelburg RA, van Stein D, Zupanska B, et al. Female donors and transfusion-related acute lung injury. *Transfusion*. 2010;50:2447-2454.
123. Silliman CC, Bjornsen AJ, Wyman TH, et al. Plasma and lipids from stored platelets cause acute lung injury in an animal model. *Transfusion*. 2003;43:633-640.
124. Silliman CC, Voelkel NF, Allard JD, et al. Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. *J Clin Invest*. 1998;101:1458-1467.
125. Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. *Blood*. 2006;108:2455-2462.
126. Silliman CC, Kelher M. The role of endothelial activation in the pathogenesis of transfusion-related acute lung injury. *Transfusion*. 2005;45:109S-116S.
127. Looney MR, Matthay MA. Animal models of transfusion-related acute lung injury. *Crit Care Med*. 2006;34:S132-S136.
128. Mair DC, Hirschler N, Eastlund T. Blood donor and component management strategies to prevent transfusion-related acute lung injury (TRALI). *Crit Care Med*. 2006;34:S137-S143.
129. Rao RS, Howard CA, Teague TK. Pulmonary endothelial permeability is increased by fluid from packed red blood cell units but not by fluid from clinically available washed units. *J Trauma*. 2006;60:851-858.
130. Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. *N Engl J Med*. 2008;358:1229-1239.
131. Snyder EL, Hedberg SL, Napychank PA, et al. Stability of red cell antigens and plasma coagulation factors stored in a non-diethylhexyl phthalate-plasticized container. *Transfusion*. 1993;33:515-519.
132. Akahoshi M, Takanashi M, Masuda M, et al. A case of transfusion-associated graft-versus-host disease not prevented by white cell-reduction filters. *Transfusion*. 1992;32:169-172.
133. Hammer JH, Mynster T, Reimert CM, Pedersen AN, Nielsen HJ. Reduction of bioactive substances in stored donor blood: prestorage versus bedside leucofiltration. *Eur J Haematol*. 1999;63:29-34.
134. Edvardsen L, Taaning E, Dreier B, Christensen LD, Mynster T, Nielsen HJ. Extracellular accumulation of bioactive substances during preparation and storage of various platelet concentrates. *Am J Hematol*. 2001;67:157-162.
135. Vamvakas EC. Possible mechanisms of allogeneic blood transfusion-associated postoperative infection. *Transfus Med Rev*. 2002;16:144-160.
136. Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. *J Clin Invest*. 2002;109:41-50.
137. Hebert PC, Fergusson D, Blajchman MA, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. *JAMA*. 2003;289:1941-1949.
138. van Hilten JA, van de Watering LM, van Bockel JH, et al. Effects of transfusion with red cells filtered to remove leucocytes: randomised controlled trial in patients undergoing major surgery. *BMJ*. 2004;328:1281.